HLX97
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for HLX97, covering 2026-03-18 to 2026-03-18. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor [Phase 1]